Stockscreener 앱 받기
188.63
1.26%
2.34
시간 외 거래:
188.63
전일 마감가:
$186.29
열려 있는:
$188.92
하루 거래량:
3.88M
Relative Volume:
2.90
시가총액:
$27.36B
수익:
$5.54B
순이익/손실:
$1.52B
주가수익비율:
18.18
EPS:
10.3734
순현금흐름:
$1.74B
1주 성능:
-1.95%
1개월 성능:
-7.60%
6개월 성능:
-22.23%
1년 성능:
-24.81%
1일 변동 폭
$187.01
$190.36
1주일 범위
$184.65
$197.41
52주 변동 폭
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
명칭
Resmed Inc
전화
(858) 746-2400
주소
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
188.63 | 27.36B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
406.78 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
143.98 | 39.67B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.68 | 31.54B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.94 | 30.39B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | JP Morgan | Overweight |
| 2025-12-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 개시 | Citigroup | Buy |
| 2025-09-02 | 업그레이드 | CLSA | Hold → Outperform |
| 2025-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 개시 | Morgan Stanley | Overweight |
| 2025-01-16 | 개시 | Goldman | Buy |
| 2025-01-10 | 개시 | Piper Sandler | Neutral |
| 2024-12-13 | 개시 | Stifel | Hold |
| 2024-09-24 | 개시 | Robert W. Baird | Outperform |
| 2024-09-18 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-25 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-24 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | 업그레이드 | Needham | Hold → Buy |
| 2023-09-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 개시 | UBS | Buy |
| 2023-04-14 | 개시 | Mizuho | Buy |
| 2023-01-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-10-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-09-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-08-15 | 다운그레이드 | CLSA | Buy → Outperform |
| 2022-08-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-28 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-01-13 | 업그레이드 | CLSA | Outperform → Buy |
| 2022-01-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2021-10-22 | 업그레이드 | CLSA | Underperform → Outperform |
| 2021-08-02 | 다운그레이드 | CLSA | Outperform → Sell |
| 2021-08-02 | 다운그레이드 | Needham | Buy → Hold |
| 2021-07-28 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 개시 | RBC Capital Mkts | Underperform |
| 2021-06-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-06-22 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2021-06-22 | 개시 | Robert W. Baird | Neutral |
| 2021-06-21 | 재확인 | Needham | Buy |
| 2021-06-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-09 | 업그레이드 | CLSA | Sell → Outperform |
| 2021-05-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Needham | Hold → Buy |
| 2020-11-02 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-10-27 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-05-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 개시 | CLSA | Underperform |
| 2020-01-31 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Perform |
| 2019-11-22 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | 업그레이드 | UBS | Neutral → Buy |
| 2019-07-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-05-06 | 업그레이드 | UBS | Neutral → Buy |
| 2019-04-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-10-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 개시 | Goldman | Buy |
모두보기
Resmed Inc 주식(RMD)의 최신 뉴스
Is ResMed (NYSE:RMD) Market Reset Creating New Interest? - Kalkine Media
Resmed Inc (RMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Resmed Inc (RMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
Is ResMed stock underperforming the Dow? - MSN
Resmed Inc (RMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Resmed Inc (RMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ResMed Is Near Its 52-Week Low Despite 21% EPS Growth: What the GLP-1 Fear Is Getting Wrong - TIKR.com
ResMed Loses Bull as Margin Outlook Moderates -- Market Talk - Moomoo
ResMed Inc (RMD) Stock Down 3.9% -- Now Undervalued? GF Score: 9 - GuruFocus
ResMed downgraded at Morgan Stanley on Philips re-entry and GLP-1 headwinds - MSN
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
Why ResMed (RMD) Shares Are Falling Today - Yahoo Finance
ResMed (RMD) Faces Downgrade Amid Market Concerns - GuruFocus
ResMed Shares Fall After Morgan Stanley Downgrade - Moomoo
ResMed Inc. Stock 12‑Month Price Target Cut to $277.74, Implies 43% Upside - TradingView
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
ResMed stock downgraded at Morgan Stanley (RMD:NYSE) - Seeking Alpha
Resmed Completes Acquisition of Noctrix Health - San Diego Business Journal
Morgan Stanley Downgrades ResMed(RMD.US) to Hold Rating, Cuts Target Price to $230 - Moomoo
Morgan Stanley downgrades ResMed stock rating on margin concerns - Investing.com
Morgan Stanley Downgrades ResMed to Equalweight From Overweight, Adjusts PT to $230 From $286 - marketscreener.com
Morgan Stanley downgrades ResMed stock rating on margin concerns By Investing.com - Investing.com UK
Analyst recommendations: Block, Resmed, Applied Materials, Ge Vernova, Intel… - marketscreener.com
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Do experts rate BHP, Cochlear, and ResMed shares as buys, holds, or sells? - MSN
Citigroup Adjusts Price Target on ResMed to $270 From $340, Maintains Buy Rating - marketscreener.com
ResMed Inc. (RMD) Stock Analysis: Exploring a Potential 38.93% Upside in the Healthcare Innovator - DirectorsTalk Interviews
ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals - Yahoo Finance
Landscape Capital Management L.L.C. Sells 32,899 Shares of ResMed Inc. $RMD - MarketBeat
ResMed added as new short idea at Hedgeye - MSN
ResMed Inc. Stock (US7611521078): Ownership moves after year-to-date pressure - AD HOC NEWS
Should you continue to hold Resmed stock in your portfolio? - MSN
Milford Funds Ltd. Makes New $28.42 Million Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Nutshell Asset Management Ltd's ResMed Inc(RMD) Holding History - GuruFocus
Why Are ResMed Shares Under Pressure Despite Solid Results? - Kalkine Media
Do Wall Street analysts like ResMed stock? - MSN
ResMed (RMD) Faces Potential 30% Decline Amid Market Concerns - GuruFocus
Is ResMed Inc. (RMD) A Good Stock To Buy Now? - Insider Monkey
Is ResMed Stock Underperforming the Dow? - Barchart.com
ResMed: GLP-1 Threats Are Overstated (NYSE:RMD) - Seeking Alpha
ResMed Inc. $RMD Shares Bought by Deutsche Bank AG - MarketBeat
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
Buy, hold, sell: Resmed, Goodman Group, Westpac shares - The Motley Fool Australia
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed chairman & CEO Michael Farrell sells $968k in stock By Investing.com - Investing.com Australia
ResMed chairman & CEO Michael Farrell sells $968k in stock - Investing.com Nigeria
ResMed Inc. stock (US7611521078): Sleep apnea specialist in focus after recent earnings update - AD HOC NEWS
ResMed (NYSE:RMD) CEO Sells $968,054.36 in Stock - MarketBeat
Resmed Inc (RMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
0.84%
자본화:
|
볼륨(24시간):